Encouraging thoughtful conversations between clinicians and patients to reduce harms associated with opioid prescribing.
The opioid crisis is having devastating consequences for individuals, families, and communities across Canada. It is a complex health and social issue, and there are no simple solutions.
In response, Choosing Wisely Canada has launched Opioid Wisely, a campaign that encourages thoughtful conversation between clinicians and patients to reduce harms associated with opioid prescribing.
The Opioid Wisely campaign launched on March 1, 2018 with the support of over 30 participating organizations representing doctors, dentists, pharmacists, nurse practitioners, other health professionals, as well as patients and their families. Central to the campaign is a set of 20 specialty-specific recommendations for when the use of opioids should not be first line therapy. These recommendations cover 16 different clinical specialties.
The Opioid Wisely campaign also includes information resources to help patients have informed conversations with their clinicians about safe options for managing pain.
The Opioid Wisely campaign was initiated at the encouragement of the Pan-Canadian Collaborative on Education for Improved Opioid Prescribing.
Canadian Academy of Child and Adolescent Psychiatry | Canadian Academy of Geriatric Psychiatry | Canadian Academy of Sport and Exercise Medicine* | Canadian Anesthesiologists Society | Canadian Association of Advanced Practice Nurses | Canadian Association of Emergency Physicians | Canadian Association of Hospital Dentists* | Canadian Association of General Surgeons* | Canadian Association of Occupational Therapists | Canadian Association of Physical Medicine & Rehabilitation* | Canadian Association of Poison Control Centres | Canadian Chiropractic Association | Canadian Deprescribing Network | Canadian Headache Society* | Canadian IBD Network of Research and Growth in Quality Improvement* | Canadian Medical Association | Canadian Neurological Society* | Canadian Nurses Association | Canadian Orthopedic Association* | Canadian Pain Society | Canadian Pharmacists Association* | Canadian Physiotherapy Association | Canadian Psychiatric Association | Canadian Rheumatology Association* | Canadian Society of Clinical Chemists | Canadian Society of Hospital Pharmacists* | Canadian Society of Internal Medicine* | Society of Obstetricians and Gynaecologists of Canada* | Canadian Society of Otolaryngology-Head & Neck Surgery* | Canadian Society of Palliative Care Physicians | Canadian Society of Respiratory Therapists | Canadian* | Spine Society* | College of Family Physicians of Canada* | Families for Addiction Recovery | Institute for Safe Medication Practices Canada | Occupational Medicine Specialists of Canada* | Pan-Canadian Collaborative on Education for Improved Opioid Prescribing | Canadian Patient Safety Institute | Patients for Patient Safety Canada |
*One of the 18 organizations that have released opioid-related recommendations to date.
Do not administer opioid analgesics to patients with burn injuries without considering the co-administration of adjunctive agents, and psychological as well as physical strategies.
Reliance on opioids as the dominant or only analgesic is associated with harms including not only higher opioid requirements and significant side-effects e.g. nausea, constipation, drowsiness, but also dependence, diversion, and overdose. One should implement a multi-modal analgesic strategy including acetaminophen and NSAIDS if there are no contra-indications. One should also consider medications directed at neuropathic pain (e.g. gabapentin, pregabalin, duloxetine, amitriptyline), as well as physical (e.g. positioning) and psychological (e.g. distraction, relaxation, meditation) interventions to optimize mental health, reduce anxiety and promote effective sleep. Burns Recommendation #5
It is important to regularly review the indication and dosage of analgesia and anxiolytics (including but not limited to opioids and benzodiazepines) in patients mechanically ventilated for their burn injuries. Higher doses of opioids and benzodiazepines are associated with delays in extubation, an increased risk of systemic infections (including ventilator associated pneumonia), deep vein thrombosis, delirium, and longer hospital stays, which in turn result in deconditioning, and long-term psychological effects. Burns Recommendation #6
Don’t continue opioid analgesia beyond the immediate postoperative period or other episode of acute, severe pain.
The immediate postoperative period or acute episodes of pain typically refers to a time period of three days or less, and rarely more than seven days. Prescribe the lowest effective dose and number of doses required to address the expected pain. This recommendation does not apply to individuals already on long term or chronic opioids or opioid agonist treatment. Family Medicine Recommendation #12
Don’t initiate opioids long-term for chronic pain until there has been a trial of available non-pharmacological treatments and adequate trials of non-opioid medications.
Depending on the pain mechanism and patient co-morbidities, this can include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclics and gabapentinoids. Other non-medication modalities for managing acute, subacute and chronic pain may include exercise, weight loss, cognitive-behavioural therapy, massage therapy, physical therapy and/or spinal manipulation therapy. An opioid trial should be guided by clear criteria for monitoring the success of an opioid trial and a plan for stopping opioids if criteria are not met. Family Medicine Recommendation #13
Prolonged use of opioid analgesia beyond the immediate postoperative period or other acute pain episode is not recommended.
Opioid use poses considerable health risks to patients including opioid use disorder, overdose, and side-effects such as psychomotor impairment. While opioid analgesia may be appropriate in select circumstances, prolonged use of opioids beyond the immediate postoperative period and for chronic non-cancer pain is not recommended. Instead, clinicians and patients should consider alternative therapies, such as non-opioid pharmacologic therapy or non-pharmacologic therapies. If opioid analgesia is required, the lowest effective dose, potency, and number of doses required to address the acute pain episode should be prescribed. General Surgery recommendation #7
Don’t prescribe opioid analgesics or combination analgesics containing opioids or barbiturates as first line therapy for the treatment of migraine.
Non-steroidal anti-inflammatory drugs and triptans are recommended first line treatments for acute migraine therapy. Opioids may produce increased sensitivity to pain and increase the risk that intermittent headache attacks will become more frequent and escalate to a chronic daily headache syndrome (medication overuse headache), particularly when opioids are used on 10 days a month or more. Opioids may impair alertness and produce dependence or addiction syndromes. Headache Recommendation #2
Don’t use opioids for post-operative dental pain until optimized dose of NSAID/Acetaminophen has been used.
For post-operative dental pain, the dose and frequency of a non-opioid (ibuprofen and/or acetaminophen) analgesic should be optimized. If this is not sufficient for managing pain then an opioid may be considered. If an opioid analgesic is appropriate consider limiting the number of tablets dispensed. Hospital Dentistry Recommendation #1
Don’t initiate or escalate opioid doses for chronic non-cancer pain before optimizing non-opioid pharmacotherapy and non-pharmacologic therapy.
Evidence shows that opioids are not more effective than other analgesics for certain chronic pain conditions. Furthermore, evidence is mounting that the risks of opioid treatment, including opioid use disorder, overdose, and other previously under-recognized side effects (e.g., hyperalgesia, psychomotor impairment [which can increase the risk of fractures], myocardial infarction, sexual dysfunction) support the use of non-opioid therapy.
Thorough patient-centred discussion about risks, benefits, and expectations is essential. Hospital Pharmacy Recommendation #6.
Don’t use opioids long-term to manage abdominal pain in inflammatory bowel disease (IBD).
While opioids may be used to manage abdominal pain in select acute settings in IBD patients, their prolonged use may mask the symptoms of active IBD or its complications (e.g., bowel perforation or megacolon). Chronic opioid use has been proven ineffective for non-malignancy associated chronic pain and is associated with excess mortality. Moreover, because of their potential risk for dependence, their long-term use for managing IBD-related abdominal pain should be avoided especially in the context of the opioid crisis in North America. Inflammatory Bowel Disease Recommendation #2
Don’t initiate therapy with opioids for patients with chronic non-cancer pain unless non-opioid pharmacotherapy and other non-pharmacological options have been optimized.
Several non-opioid therapies (including both drug and non-drug alternatives) may achieve a similar magnitude of improvement in pain and function more safely without the potentially serious side effects of opioid therapy (e.g. harms related to dependence, addiction and overdose). Internal Medicine Recommendation #6
Don’t choose opioids or cannabinoids as the first choice of treatment for neuropathic pain.
Opioids and cannabinoids have weak or inconclusive evidence in effective treatment of neuropathic pain. The well documented risks of opioid and cannabinoids include nausea, sleepiness, impairment, dependence, and development of substance use disorders. With impairment comes further risks to oneself and others in altered judgement in the workplace or while operating a vehicle. Opioids come with an additional risk of decreased respiratory drive and fatality with overdose. Neuropathic pain can be treated effectively using agents with demonstrated efficacy and significantly less risks compared to opioids and cannabinoids. Neurology Recommendation #3
Don’t use opioids for treatment of migraines.
Opioids are not adequate for pain control for patients with migraines. The risk for harm, including impairment, dependence, tolerance, medication overuse headaches, and opioid use disorder with opioids is greater than the documented benefit. Additionally, opioids may worsen nausea and vomiting associated with the migraine. Prescription opioids for migraines would have minimal to no benefit with the excess of risk, and contribute to the opioid crisis. Neurology Recommendation #6
Don’t prescribe opioids for management of osteoarthritis before optimizing the use of non-opioid approaches to pain management.
The use of opioids in chronic non-cancer pain is associated with significant risks. Optimization of non-opioid pharmacotherapy and non-pharmacologic therapy is strongly recommended. Treatment with opioids is not superior to treatment with non-opioid medications in improving pain-related function over 12 months in patients with moderate to severe hip, knee or back pain due to osteoarthritis. Orthopaedics Recommendation #4
Don’t use meperidine for labour analgesia due to its long-acting active metabolites and negative effects on neonatal behaviours.
Meperidine (Demerol) as an opioid analgesic relieves pain of labour but there are superior agents. Furthermore it passes to the fetus and has a particularly long time before elimination. It persists in the neonate and thus interferes with adaptation to extrauterine life and adversely affects breast feeding. Because there are superior choices for analgesia without these adverse effects, meperidine should not be used if alternatives are available. Obstetrics and Gynaecology Recommendation #5
Don’t prescribe opiates for the treatment of acute or chronic non-cancer pain without first assessing side effects, work status, and capacity to drive a motor vehicle.
Increases in opioid prescribing have been accompanied by simultaneous increases in abuse, serious injuries, and deaths from overdose. Compared to those on no, or lower opiate doses, those prescribed higher opiate doses have increased disability risk and duration. The use of opiates can result in effects such as euphoria, drowsiness or inability to concentrate. Cognitive and psychomotor ability are essential functions for driving a motor vehicle and other complex work tasks. Those who prescribe opiates may be obligated to report a patient’s inability to drive safely. Occupational Medicine Recommendation #2
Don’t recommend the use of over-the-counter medications containing codeine for the management of acute or chronic pain. Counsel patients against their use and recommend safe alternatives.
There is no evidence to support the use of low-dose codeine pain medication over non-opioid analgesics. Codeine is an addictive opioid with potential for abuse and dependence. Over-the-counter codeine products are often supplied in combination with non-opioid analgesics (i.e., NSAIDs and acetaminophen). In addition to concerns regarding codeine abuse and dependence, misuse of these codeine-containing combination analgesics may also result in serious adverse effects due to high doses of the simple analgesics (ibuprofen, acetaminophen or aspirin). Effects of high doses of simple analgesics may include liver toxicity, gastric perforation, haemorrhage and peptic ulcer, renal failure, chronic blood loss anaemia and low blood potassium (with potential fatal heart and neurological complications). Pharmacist Recommendation #2
Don’t order prescription drugs for pain without considering functional improvement.
Prescription pain medications have been shown to be effective for pain relief. However, a number of adverse events have been established. While pain reduction is an important outcome measure for patients, they also highly value improved function and quality of life. The addition of prescription pain medications does not always improve functional outcomes, or even pain. There is also a significant risk of long-term addiction. It is imperative that providers work with patients to establish treatment goals, regularly reassess pain and function, and taper or discontinue medications as able or if patients experience harm. Physical Medicine and Rehabilitation Recommendation #3
Don’t prescribe codeine for post-tonsillectomy/adenoidectomy pain relief in children.
Codeine has been associated with a high rate of adverse drug reactions in children. This includes life-threatening respiratory depression. Appropriate dosing of codeine is challenging due to the genetic heterogeneity amongst patients for the CYP2D6 enzyme, which is responsible for codeine metabolism. Genetic screening of CYP2D6 is not routinely performed and can not reliably identify variations in codeine metabolism rates amongst patients. As such, children who are ultra-fast metabolizers of codeine are placed at increased risk of severe adverse drug reactions. Alternative analgesia should be used post-tonsillectomy/adenoidectomy. Pediatric Otolaryngology Recommendation #6
Don’t prescribe opioids for management of chronic rheumatic disease before optimizing the use of non-opioid approaches to pain management.
Opioids in chronic non-cancer pain are associated with substantial risks. Optimize non-opioid pharmacotherapy and non-pharmacologic therapy. Opioids are not superior to non-opioid medications for pain-related function over 12 months in moderate to severe hip or knee osteoarthritis, or mechanical back pain. Opioids should only be prescribed by physicians skilled in their use. Rheumatology Recommendation #6
Don’t prescribe opiates as first line treatment for tendinopathies.
Tendinopathy is a broad term encompassing painful conditions occurring in and around tendons in response to overuse. Although acute inflammatory tendinopathies (i.e., tendinitis) exist, most patients seen in primary care will have chronic symptoms (tendinosis). Multimodality options (e.g., relative rest, activity modifications, physical or athletic therapy, etc.) should be considered as the first line treatment of tendinopathies. Opiates should not be used in the initial phase of treatment. Sport and Exercise Medicine Recommendation #2